This article is intended for researchers and laboratory professionals. All peptides discussed are for research use only (RUO) and are not approved for human administration, therapeutic use, or clinical application. PeptidesLab UK supplies research-grade GHK-Cu for in vitro and in vivo laboratory investigations only.
GHK-Cu Biology: Copper-Glycyl-L-Histidyl-L-Lysine and Tissue Repair Signalling
GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper(II) complex, MW 340 Da as free tripeptide, ~403 Da as Cu²⁺ chelate) is an endogenous plasma tripeptide with picomolar-nanomolar affinity for Cu²⁺ (Kd ~10⁻¹⁵ M by potentiometry and ITC), maintaining tissue copper in a bioavailable, non-toxic form. GHK circulates at ~200 ng/mL in young adults declining to ~80 ng/mL in elderly subjects (ELISA, competitive immunoassay), with Cu²⁺ loading producing the biologically active GHK-Cu complex at 1:1 stoichiometry confirmed by UV-Vis spectroscopy (broad d-d absorption 580-620 nm, ε ~50 M⁻¹cm⁻¹) and ESI-MS. For wound healing research, GHK-Cu occupies a mechanistically distinct position from growth factor-based approaches: it does not bind a single high-affinity receptor but instead modulates gene expression broadly (upregulating ~31% and downregulating ~57% of the human genome in microarray studies at 1-10 μM), with particular enrichment of wound healing, antioxidant, and anti-inflammatory pathways in the upregulated set.
The proposed mechanisms of GHK-Cu’s wound-healing activity converge on: (i) copper delivery to lysyl oxidase (LOX) — the copper-dependent enzyme crosslinking collagen and elastin in the extracellular matrix; (ii) stimulation of metalloproteinase (MMP) activity at low concentrations (ECM remodelling) while inhibiting MMPs at high concentrations; (iii) upregulation of growth factor genes including VEGF-A, FGF-2, TGF-β1, PDGF-β, and EGF in fibroblasts and keratinocytes; (iv) activation of the Wnt/β-catenin pathway in dermal fibroblasts; and (v) NF-κB inhibition reducing pro-inflammatory cytokine production in macrophages and keratinocytes.
Fibroblast Research: Collagen, MMP Regulation and Wound Contraction
Human dermal fibroblast (HDF) research with GHK-Cu employs primary HDFs (Lonza CC-2511, ATCC PCS-201-012, passage 4-8) and Hs68 foreskin fibroblasts. GHK-Cu (0.1 nM to 10 μM dose range — critical to study full dose range as GHK-Cu responses are characteristically U-shaped/hormetic) in serum-reduced (0.5-2% FBS) conditions for 24-72h.
Collagen endpoints: COL1A1 and COL3A1 mRNA qPCR (Taqman); Sircol total collagen assay (conditioned media, Biocolor S1000, OD555); procollagen type I C-terminal propeptide (PICP) ELISA (MicroVue Quidel) as secreted collagen proxy; hydroxyproline content (Sigma MAK008, cell layer acid hydrolysis); immunofluorescence (anti-collagen I, Abcam ab34710, fibrillar organisation by SHG confocal second harmonic generation). LOX activity in GHK-Cu-treated fibroblast conditioned media: fluorometric LOX assay (Amplex Red, H₂O₂-coupled HRP, excitation 530 nm emission 590 nm) confirming copper delivery to LOX active site.
MMP regulation: MMP-1, MMP-2, MMP-9 and MMP-13 ELISA (R&D Systems) in conditioned media at 24h and 48h; MMP-2 and MMP-9 gelatin zymography (10% acrylamide + 0.1% gelatin, renaturing 2.5% Triton X-100 1h, developing buffer 24h 37°C, Coomassie staining, inverted clear band % activity); TIMP-1 and TIMP-2 ELISA (MMP:TIMP molar ratio as ECM remodelling index). GHK-Cu at 1-100 nM: pro-remodelling (MMP elevation, TIMP suppression); at 1-10 μM: anti-remodelling and anti-fibrotic (MMP suppression, TIMP elevation) — the dose-dependent switch is critical for wound research design.
Wound contraction: 3D collagen lattice contraction assay (type I collagen 2 mg/mL, HDF 2.5×10⁵/mL, polymerised in 24-well plate 1h 37°C, released from wells at 0h, area measured by ImageJ at 0, 24, 48, 72h as % of initial area — contraction reflects myofibroblast differentiation). TGF-β1 (5 ng/mL, positive contraction control) and blebbistatin (myosin II inhibitor, 50 μM, negative control) frame the biological range. GHK-Cu effects on lattice contraction assess myofibroblast activation biology.
Keratinocyte Re-Epithelialisation: Migration, Proliferation, and Differentiation
Re-epithelialisation is kinetically the rate-limiting step in wound closure. GHK-Cu keratinocyte research employs HaCaT (spontaneously immortalised, ATCC), primary NHEK (normal human epidermal keratinocytes, Lonza KK-4009, passage 2-5), and N/TERT-1 (hTERT-immortalised primary keratinocytes) cell lines.
Migration: scratch wound assay (P200 pipette tip, IncuCyte S3 2h-interval phase-contrast imaging, % confluence restoration at 12, 24, 48h) with mitomycin-C 10 μg/mL pre-treatment (2h, washed) isolating migration from proliferation; modified Boyden transwell (8 μm PET, collagen I 10 μg/mL-coated lower surface for keratinocyte adhesion, EGF 10 ng/mL lower chamber chemotaxis control). GHK-Cu (1 nM-1 μM) enhancement of migration: EGFR Tyr-1068 phosphorylation western (Cell Signaling 3777) and EGFR ligand (HB-EGF, amphiregulin) ELISA in conditioned media — ADAM-mediated EGFR transactivation as GHK-Cu signalling mechanism. Keratinocyte proliferation: BrdU ELISA (24h BrdU pulse), Ki-67 IF (% positive, n≥200 cells counted), EdU Click-iT flow (S-phase %). Differentiation: involucrin and filaggrin mRNA qPCR (late differentiation markers) and K14/K10 IF (K14=basal, K10=suprabasal, ratio quantifies differentiation state).
🔗 Related Reading: For a comprehensive overview of GHK-Cu biology, mechanisms, UK sourcing, and research applications, see our GHK-Cu Research Guide UK.
Angiogenesis Research: VEGF-A Induction and Endothelial Biology
Wound angiogenesis is driven primarily by VEGF-A (vascular endothelial growth factor A) released from hypoxic wound keratinocytes and macrophages. GHK-Cu upregulates VEGF-A mRNA (qPCR, Taqman Hs00900055_m1) and protein (ELISA, R&D Systems DVE00) in fibroblasts and keratinocytes through HIF-1α-independent mechanisms — proposed to involve SP1 (specificity protein 1) transcription factor binding to GC-rich elements in the VEGF-A promoter, activated by GHK-Cu-driven Cu²⁺-cuproenzyme modulation of the redox-sensitive SP1 pathway. HIF-1α protein western (anti-HIF-1α, Cell Signaling 14179, normoxic and 1% O₂ hypoxic conditions) with and without GHK-Cu treatment distinguishes HIF-1α-dependent from -independent VEGF-A induction.
Endothelial angiogenesis assays: HUVEC tube formation (Matrigel GFR 96-well, IncuCyte tube length/branch points 4-16h, VEGF-A 50 ng/mL positive control, SU5416 VEGFR2 inhibitor 1 μM negative control); HUVEC proliferation (BrdU/MTT); aortic ring (C57BL/6 thoracic aortic rings in Matrigel, GHK-Cu loaded gelatin sponge, microvessel sprouting length day 5-7 by brightfield stereomicroscope); and CAM (chick chorioallantoic membrane, fertilised day 8, methylcellulose disc containing GHK-Cu, day 12 stereomicroscope vessel count and vascular index). Anti-VEGFR2 monoclonal DC101 (20 mg/kg i.p., comparator for VEGF-A-independent components of GHK-Cu angiogenesis) and bevacizumab (anti-VEGF-A, 10 μg/mL in vitro) neutralisation dissection of VEGF-A-dependent versus independent GHK-Cu endothelial effects.
Macrophage Polarisation and Anti-Inflammatory Research
The inflammatory phase of wound healing (days 1-5, neutrophil then macrophage infiltration) transitions to the proliferative phase through macrophage M1→M2 polarisation shift. GHK-Cu accelerates this transition in research models. THP-1 PMA-differentiated macrophages or primary BMDM (C57BL/6, tibial/femoral flush, M-CSF 30 ng/mL 7d): M1 polarisation (LPS 100 ng/mL + IFN-γ 20 ng/mL) ± GHK-Cu (1-1000 nM pre-treatment 24h). Primary endpoints: NF-κB p65 nuclear western and confocal IF (nuclear:cytoplasmic ratio); Luminex TNF-α-IL-1β-IL-6-IL-10-MCP-1-IL-12p70 at 6h and 24h; iNOS western (inducible NO synthase, M1 marker); CD80+CD86+CD206+CD163+ flow cytometry surface phenotyping. GHK-Cu at 10-100 nM reduces M1 cytokines (TNF-α, IL-1β, IL-6) and iNOS, while increasing IL-10 and CD206+ — confirming M1→M2 shift. The Cu²⁺ itself (CuCl₂, equimolar) versus GHK alone (without Cu²⁺) versus GHK-Cu complex comparison establishes that the intact complex (not free Cu²⁺ or free GHK alone) is responsible for the full anti-inflammatory effect.
In Vivo Wound Healing Models and Topical Delivery Research
Excisional wound models (C57BL/6, dorsal splinted 6 mm biopsy punch, silicone ring Grace Bio-Labs, 12 mm): GHK-Cu topical application (1-100 μg/wound in hydrogel vehicle: 0.5% Carbopol 980, pH 6.0, carboxymethylcellulose 2% w/v, or hyaluronic acid 1% w/v) applied daily from day 0. Digital planimetry (Nikon D750, ImageJ area %) at days 3, 7, 10, 14. Histological endpoints (4% PFA, paraffin, 5 μm): H&E (re-epithelialisation distance μm, granulation tissue depth μm, inflammatory cell density per 0.1 mm² field); Masson trichrome (collagen density %area); CD31 IHC (neovessel density vessels/mm²); α-SMA IHC (myofibroblast density, granulation border zone); Ki-67 IHC (proliferating cells/field) at days 7 and 14.
Diabetic wound model (STZ 55 mg/kg i.p., C57BL/6, 4-week hyperglycaemia confirmation blood glucose >15 mmol/L, then wound): impaired wound healing in diabetes reflects reduced growth factor production, macrophage dysfunction, and oxidative stress — all targets for GHK-Cu. GHK-Cu topical delivery in STZ-diabetic versus normoglycaemic comparison with matched positive control (becaplermin 0.01% PDGF-BB gel, Regranex — FDA-approved chronic wound treatment) establishes GHK-Cu’s relative efficacy in the clinically relevant impaired healing context. Wound oxidative stress (nitrotyrosine IHC, 4-hydroxynonenal IHC, MDA-TBARS in wound tissue homogenate) as mechanism biomarkers at 7d.
Transcriptomic Profiling and Gene Expression Research
GHK-Cu’s broad transcriptomic effects make it a valuable research tool for gene expression studies. RNA-seq (Illumina NovaSeq, 20 million reads/sample, DESeq2 differential expression, FDR q<0.05, |log₂FC|>0.5) in GHK-Cu-treated (1 μM, 24h) versus vehicle HDF or primary skin fibroblasts. Gene Ontology (GO) enrichment (g:Profiler, GSEA) identifies upregulated pathways: wound healing (GO:0042060), extracellular matrix organisation (GO:0030198), response to oxidative stress (GO:0006979), and angiogenesis (GO:0001525). Downregulated pathways: inflammatory response (GO:0006954), NF-κB signalling (GO:0051092), and cancer hallmarks (GO:2001234 — GHK-Cu has been proposed to suppress cancer-associated transcriptomic signatures). Single-gene validation by RT-qPCR (minimum 10 targets from each enriched pathway) confirms RNA-seq findings with endogenous reference gene normalisation (GAPDH + ACTB + HPRT1 geometric mean).
Control Design and Research Rigour
Rigorous GHK-Cu wound healing research requires: (i) full dose-response curves — at minimum 8 concentrations spanning 0.1 nM to 10 μM to capture the characteristic hormetic/U-shaped response; (ii) GHK alone vs CuCl₂ alone vs GHK-Cu complex — each tested at equimolar concentrations to identify Cu²⁺-specific, GHK-specific, and synergistic (complex-specific) effects; (iii) Cu²⁺ chelation control — tetrathiomolybdate (TTM) or bathocuproinedisulphonate (BCS, copper chelator, 100 μM) in GHK-Cu-treated cells confirms that Cu²⁺ delivery is required for biological activity; (iv) LOX activity validation — β-aminopropionitrile (BAPN, irreversible LOX inhibitor, 200 μM) co-treatment confirms LOX-dependent collagen crosslinking component of GHK-Cu’s ECM effects; (v) peptide quality — GHK-Cu complex confirmed by UV-Vis spectroscopy (d-d band 580-620 nm), ESI-MS (correct m/z for GHK-Cu chelate), RP-HPLC ≥95% purity; (vi) vehicle controls — hydrogel vehicle at matched carrier concentration, applied identically; (vii) in vivo copper homeostasis monitoring — serum copper (ICP-MS) and ceruloplasmin (ELISA) in animals receiving GHK-Cu confirming physiological copper levels are maintained without copper toxicity from chronic topical exposure.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified GHK-Cu for research and laboratory use. View UK stock →
